JAMA:巴氯芬对ICU患者焦躁不安相关事件风险的影响

2021-02-24 MedSci原创 MedSci原创

对于接受ICU机械通气的酗酒患者,大剂量巴氯芬治疗可显著减少焦躁不安相关事件风险,但同时会导致患者机械通气时间和ICU治疗时间延长

巴氯芬可用于缓解由多种疾病引起的骨骼肌痉挛,近日研究人员考察了大剂量巴氯芬对接受机械通气酗酒患者躁动相关事件的影响。
 
本次研究在法国18个ICU中心进行,为III期、双盲、安慰剂对照、随机研究,参与者为在ICU接受治疗的酗酒患者,患者接受机械通气,随机接受巴氯芬(n=159)或安慰剂(n=155),其中巴氯芬组患者根据肾小球滤过率调整药物剂量,剂量范围从50毫克/天至150毫克/天。研究的主要终点为出现至少1次焦虑不安相关事件的患者百分比,次要终点包括机械通气持续时间、ICU住院时间和28天死亡率。
 
314名患者参与研究,平均年龄57岁,女性60名(17.2%),313名(99.7%)完成了试验。与安慰剂组相比,巴氯芬组至少经历过1次焦虑不安相关事件的患者百分比在统计学上显著降低(31例vs46例,19.7% vs29.7%;差异-9.93%;校正比值比,0.59)。预先设定的18项次要终点中,14个无显著差异,但与安慰剂组相比,巴氯芬组的机械通气时间(9天vs 8天)和在ICU治疗时间明显延长(14天 vs 11天)。28天时,组间死亡率无显著差异(25.3% vs 21.6%;校正比值比1.24)。巴氯芬组有14名患者(8.9%)出现苏醒延迟(停止使用镇静剂72小时后没有睁眼),安慰剂组有3名患者(1.9%)出现苏醒延迟。
 
研究认为,对于接受ICU机械通气的酗酒患者,大剂量巴氯芬治疗可显著减少焦躁不安相关事件风险,但同时会导致患者机械通气时间和ICU治疗时间延长。
 
原始出处
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694775, encodeId=67571694e753a, content=<a href='/topic/show?id=87754830349' target=_blank style='color:#2F92EE;'>#巴氯芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48303, encryptionId=87754830349, topicName=巴氯芬)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1929746222, createdName=zhyy98, createdTime=Sun May 30 13:01:16 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595385, encodeId=13d3159538504, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 26 10:01:16 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036471, encodeId=ab2a10364e17d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Feb 24 22:01:16 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926929, encodeId=b7f9926929df, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Feb 24 19:49:08 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926923, encodeId=f96192692375, content=术业有专攻!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/03/cf6cf5d63bbf3ec8acd12776cb4830e2.jpg, createdBy=9b012235590, createdName=12131f9bm89(暂无昵称), createdTime=Wed Feb 24 19:28:33 CST 2021, time=2021-02-24, status=1, ipAttribution=)]
    2021-05-30 zhyy98
  2. [GetPortalCommentsPageByObjectIdResponse(id=1694775, encodeId=67571694e753a, content=<a href='/topic/show?id=87754830349' target=_blank style='color:#2F92EE;'>#巴氯芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48303, encryptionId=87754830349, topicName=巴氯芬)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1929746222, createdName=zhyy98, createdTime=Sun May 30 13:01:16 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595385, encodeId=13d3159538504, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 26 10:01:16 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036471, encodeId=ab2a10364e17d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Feb 24 22:01:16 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926929, encodeId=b7f9926929df, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Feb 24 19:49:08 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926923, encodeId=f96192692375, content=术业有专攻!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/03/cf6cf5d63bbf3ec8acd12776cb4830e2.jpg, createdBy=9b012235590, createdName=12131f9bm89(暂无昵称), createdTime=Wed Feb 24 19:28:33 CST 2021, time=2021-02-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1694775, encodeId=67571694e753a, content=<a href='/topic/show?id=87754830349' target=_blank style='color:#2F92EE;'>#巴氯芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48303, encryptionId=87754830349, topicName=巴氯芬)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1929746222, createdName=zhyy98, createdTime=Sun May 30 13:01:16 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595385, encodeId=13d3159538504, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 26 10:01:16 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036471, encodeId=ab2a10364e17d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Feb 24 22:01:16 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926929, encodeId=b7f9926929df, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Feb 24 19:49:08 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926923, encodeId=f96192692375, content=术业有专攻!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/03/cf6cf5d63bbf3ec8acd12776cb4830e2.jpg, createdBy=9b012235590, createdName=12131f9bm89(暂无昵称), createdTime=Wed Feb 24 19:28:33 CST 2021, time=2021-02-24, status=1, ipAttribution=)]
    2021-02-24 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1694775, encodeId=67571694e753a, content=<a href='/topic/show?id=87754830349' target=_blank style='color:#2F92EE;'>#巴氯芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48303, encryptionId=87754830349, topicName=巴氯芬)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1929746222, createdName=zhyy98, createdTime=Sun May 30 13:01:16 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595385, encodeId=13d3159538504, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 26 10:01:16 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036471, encodeId=ab2a10364e17d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Feb 24 22:01:16 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926929, encodeId=b7f9926929df, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Feb 24 19:49:08 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926923, encodeId=f96192692375, content=术业有专攻!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/03/cf6cf5d63bbf3ec8acd12776cb4830e2.jpg, createdBy=9b012235590, createdName=12131f9bm89(暂无昵称), createdTime=Wed Feb 24 19:28:33 CST 2021, time=2021-02-24, status=1, ipAttribution=)]
    2021-02-24 医鸣惊人

    认真学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1694775, encodeId=67571694e753a, content=<a href='/topic/show?id=87754830349' target=_blank style='color:#2F92EE;'>#巴氯芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48303, encryptionId=87754830349, topicName=巴氯芬)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1929746222, createdName=zhyy98, createdTime=Sun May 30 13:01:16 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595385, encodeId=13d3159538504, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Fri Feb 26 10:01:16 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036471, encodeId=ab2a10364e17d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Feb 24 22:01:16 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926929, encodeId=b7f9926929df, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Feb 24 19:49:08 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926923, encodeId=f96192692375, content=术业有专攻!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/03/cf6cf5d63bbf3ec8acd12776cb4830e2.jpg, createdBy=9b012235590, createdName=12131f9bm89(暂无昵称), createdTime=Wed Feb 24 19:28:33 CST 2021, time=2021-02-24, status=1, ipAttribution=)]
    2021-02-24 12131f9bm89(暂无昵称)

    术业有专攻!

    0

相关资讯

Stroke:鞘内注射巴氯芬治疗卒中后疼痛

卒中是成人疼痛和残疾的主要原因,这会到之后广泛的身体、情绪和社会经济上的问题。卒中后疼痛的原因复杂,可能和骨骼肌、中枢神经有关,或因为肌肉张力高痉挛状态。卒中后遗症会对患者的生活质量(quality of life,QoL)造成负面影响;原因是多方面的,直接相关的原因包括活动减少、无法自我护理和日常生活活动、社会关系减少、以及一些主观症状蔽日疼痛、疲劳和抑郁。

Am J Gastroenterol:巴氯芬可缓解反刍综合征症状

研究认为巴氯芬可通过改变食道下端括约肌压力,缓解反刍综合征症状

JAMA:巴氯芬与老年CKD患者脑病风险

巴氯芬导致老年慢性肾脏病患者脑病风险增加